Loading stock data…
$4.70-0.02 (-0.53%)
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
Cingulate Inc. in the Healthcare sector is trading at $4.70 with a market capitalization of $75M. Wall Street consensus targets $21.20 (5 analysts), implying a +351.5% move over the next 12 months. The stock is currently near its 52-week low of $3.16, remaining 13.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.41M↑ | -$7.92M↓ | -$5.59M↑ | -$6.00M↓ | -$4.65M |
| Net Income | -$5.87M↑ | -$9.31M↓ | -$6.27M↑ | -$7.34M↓ | -$4.98M |
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead produc...